Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The companyâs lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naĂŻve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Pointâs kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. Source
No articles found.
Apyx⢠Medical Corporation (formerly known as BovieŽ Medical Corporation) is an ...
Apyx⢠Medical Corporation (formerly known as ...
Amedisys, Inc. is a leading healthcare at home Company delivering personalized hom...
Amedisys, Inc. is a leading healthcare at home ...
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-bas...
Genomic Health, Inc. (NASDAQ: GHDX) is the worl...
Trovagene is a clinical-stage, oncology therapeutics company, taking a precision m...
Trovagene is a clinical-stage, oncology therape...
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on a...
Concert Pharmaceuticals is a clinical stage bio...
Collegium Pharmaceutical is a specialty pharmaceutical company committed to being ...
Collegium Pharmaceutical is a specialty pharmac...
Nemucore Medical Innovations is here to bring you the future of cancer care. Theyâ...
Nemucore Medical Innovations is here to bring y...
Join the National Investor Network and get the latest information with your interests in mind.